**February 20, 2018**
14-16 February 2018 InSysBio held Annual Internal Scientific Meeting.
Results of the last year have been discussed and summarized. In 2017 we collaborated with seven international pharmaceutical companies in framework of eight projects. Seven pharmaceutical companies began to use Immune Response Template 1.0, a platform for QSP modeling in immunology and immuno-oncology developed by InSysBio. Three research papers have been published in CPT: Pharmacometrics & Systems Pharmacology and Journal of Controlled Release.
We have discussed the progress in ongoing projects such as QSP model of Alzheimer’s Disease (including amyloid beta and tau description), modeling of T cells and CAR-T therapy in oncology, development of QSP modeling software and other projects. This Annual Internal Scientific Meeting was the 11th held by InSysBio.
| ← | September 2017 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
| ||||
|
4
|
5
|
6
|
7
|
8
|
9
|
10
|
|
11
|
12
|
13
|
14
|
15
|
16
|
17
|
|
18
|
19
|
20
|
21
|
22
|
23
|
24
|
|
25
|
26
|
27
|
28
1.
28 Sep 2017 19:27
Computer model showed an optimal anti-amyloid treatment
Moscow, Russia, September 28, 2017. One must activate amyloid degradation as soon as possible to prevent the appearance of the protein plaques in brain under Alzheimer’s conditions. This conclusion was reached by scientists from the biotechnology company InSysBio, who created the first computer model of the disease. The final part of the work has been recently published in CPT: Pharmacometrics & Systems Pharmacology.
|
29
|
30
| |
Thank you for your message! We will get back to you shortly.
